Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Background: Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication: Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer

Associated Therapies: -

Clinical Trials

Rotating Pazopanib and Everolimus to Avoid Resistance

Phase 2

Completed

Conditions: Clear Cell Renal Carcinoma

Interventions: Drug: Pazopanib
Drug: Everolimus

First Posted Date: 2011-08-02

Last Posted Date: 2014-07-16

Lead Sponsor: Netherlands Working Group on Immunotherapy of Oncology

Target Recruit Count: 101

Registration Number: NCT01408004

Locations: 🇳🇱
St. Franciscus Gasthuis, Rotterdam, Zuid-Holland, Netherlands
🇳🇱
Medisch Centrum Alkmaar, Alkmaar, Netherlands
🇳🇱
Haga Ziekenhuis, Den Haag, Netherlands

and more 14 locations

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor - Protocol Specific
Breast Cancer - Female

Interventions: Drug: Pazopanib
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2011-08-02

Last Posted Date: 2022-09-28

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 34

Registration Number: NCT01407562

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

HYPAZ: Hypertension Induced by Pazopanib

Phase 2

Terminated

Conditions: Ovarian Cancer
Pancreatic Cancer
Glioblastoma
Gastrointestinal Cancer
Breast Cancer
Renal Cell Carcinoma
Non-small Cell Lung Cancer
Soft Tissue Sarcoma
Cervical Cancer
Small Cell Lung Cancer

Interventions: Drug: Pazopanib

First Posted Date: 2011-07-12

Last Posted Date: 2020-02-13

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 31

Registration Number: NCT01392352

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: Temsirolimus
Drug: Pazopanib
Behavioral: Quality of Life Assessment
Drug: Benadryl

First Posted Date: 2011-07-12

Last Posted Date: 2021-09-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT01392183

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Phase 2

Terminated

Conditions: Gastrointestinal Stromal Tumor (GIST)

Interventions: Drug: Pazopanib

First Posted Date: 2011-07-12

Last Posted Date: 2017-04-07

Lead Sponsor: Kristen Ganjoo

Target Recruit Count: 25

Registration Number: NCT01391611

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pazopanib, Docetaxel, Prednisone Prostate

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Pazopanib
Drug: Docetaxel
Drug: Prednisone
Drug: Pegfilgrastim

First Posted Date: 2011-06-30

Last Posted Date: 2018-06-06

Lead Sponsor: Daniel George, MD

Target Recruit Count: 36

Registration Number: NCT01385228

Locations: 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸
The University of Chicago, Chicago, Illinois, United States

Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Pazopanib

First Posted Date: 2011-06-21

Last Posted Date: 2011-06-21

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 45

Registration Number: NCT01377298

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Pazopanib

First Posted Date: 2011-05-26

Last Posted Date: 2018-04-25

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT01361113

Locations: 🇺🇸
North Carolina Cancer Hospital (UNC), Chapel Hill, North Carolina, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Pazopanib

First Posted Date: 2011-05-26

Last Posted Date: 2021-04-08

Lead Sponsor: University Hospital Muenster

Target Recruit Count: 20

Registration Number: NCT01361334

Locations: 🇩🇪
Unviersity Hospital of Münster (UKM), Münster, Germany

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Pazopanib
Drug: Vorinostat

First Posted Date: 2011-04-21

Last Posted Date: 2017-06-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 152

Registration Number: NCT01339871

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy